Akari Therapeutics Plc

Akari Therapeutics Plc is an oncology biotechnology company focused on the development of next-generation antibody-drug conjugates (ADCs). The company utilizes an innovative ADC discovery platform to create precision bifunctional ADC candidates for the treatment of various cancers. Akari Therapeutics is headquartered in Tampa, Florida.

Akari's pipeline is centered around its proprietary PH1 payload, a novel spliceosome modulator designed to disrupt RNA splicing within cancer cells, induce tumor-specific cell death, and activate the immune system. Its lead candidate, AKTX-101, is a TROP2-targeting ADC that delivers the PH1 payload directly into tumors. The company is also developing AKTX-102, an ADC candidate targeting CEACAM5.

Following its merger with Peak Bio Inc. in November 2024, Akari Therapeutics shifted its strategic focus to oncology and its ADC platform. Abizer Gaslightwala serves as the President and Chief Executive Officer, appointed in April 2025. In May 2026, the company reported promising preclinical data for AKTX-101, demonstrating synergistic tumor-killing activity when combined with KRAS inhibitors in pancreatic cancer models. Akari has initiated IND-enabling studies for AKTX-101, with a goal of commencing a First-In-Human trial by late 2026 or early 2027.